TOKYO, May 12 (Pulse News Wire) – Shionogi & CO.,LTD. (4507.T) reported a 14% increase in revenue to ¥5,000 billion for the fiscal year ended March 2026.
Operating profit rose to ¥2,003 billion compared to ¥1,739 billion in the previous fiscal year. Key drivers included strong performance in domestic pharmaceutical products, which saw a 25% rise to ¥1,235 billion, and overseas subsidiaries/export sales, up 9.9% to ¥650 billion. Notable contributions came from Shionogi Inc. in the US, growing 22.9%, and Shionogi B.V.
In Europe, increasing 23.4%. For the upcoming fiscal year ending March 2027, Shionogi forecasts revenue growth to reach ¥5.900 billion, driven by continued expansion in its domestic and international markets. The company also highlighted ongoing investment in research and development, aiming to bolster its pipeline of innovative drugs. The firm's capital increased to ¥16,862 billion, reflecting robust profitability and strategic acquisitions.
Shionogi remains committed to advancing its therapeutic areas and expanding its global footprint through targeted investments and partnerships.
🟡 Confidence: Standard AI-translated content.